SciELO - Scientific Electronic Library Online

 
vol.63 issue3BMenstrual cycle worsening of epileptic seizures in women with symptomatic focal epilepsySleep disorders are associated with impulsivity in school children aged 8 to 10 years author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

  • pdf in English
  • ReadCube
  • Article in xml format
  • Article references
  • How to cite this article
  • Curriculum ScienTI
  • Automatic translation
  • Send this article by e-mail

Indicators

Related links

Share


Arquivos de Neuro-Psiquiatria

Print version ISSN 0004-282X

Arq. Neuro-Psiquiatr. vol.63 no.3b São Paulo Sept. 2005

http://dx.doi.org/10.1590/S0004-282X2005000500007 

Seizure occurrence in patients with chronic renal insufficiency in regular hemodialysis program

 

Ocorrência de crises epilépticas em pacientes com insuficiência renal crônica em programa dialítico regular

 

 

Fulvio Alexandre ScorzaI, II; Marly de AlbuquerqueI, II; Ricardo Mario AridaI, II; Roberta Monterazzo CysneirosII; Tânia Maria Guedes HenriquesI; Carla Alessandra ScorzaII; Jener CruzIII; Silvana KesrouaniIII; Rui Alberto GomesIII; Esper Abrão CavalheiroII

ILaboratório de Neurociências. Núcleo de Pesquisas Tecnológicas/ Universidade de Mogi das Cruzes (NPT/UMC), Mogi das Cruzes, SP, Brasil
IILaboratório de Neurologia Experimental. Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM), São Paulo SP, Brasil
IIIInstituto de Nefrologia de Mogi das Cruzes, SP, Brasil

 

 


ABSTRACT

Hemodialysis-associated seizure is a complication of hemodialysis. This report describes the occurrence of seizures in patients with end stage renal disease on dialysis therapy at the Nephrology Institute of Mogi das Cruzes, São Paulo State, Brazil. A retrospective medical history of 189 patients was reviewed to investigate the occurrence of convulsive seizures during dialytic program. Seven patients with history of seizures were selected but five of them were included in our study. Three patients presented generalized tonic-clonic seizures, one had partial seizure with secondary generalization, and one presented unclassified seizure. Three patients presented seizure just during the dialysis (unique seizure) and one of them presented convulsive status epilepticus. The two other patients had already presented seizures prior the beginning of dialysis. We conclude that seizures in renal failure could be considered as occasional events that do not usually become chronic.

Key words: seizures, epilepsy, dialysis, renal failure.


RESUMO

Convulsões durante o tratamento dialítico podem constituir uma complicação da hemodiálise. Esse artigo descreve a ocorrência de crises em pacientes em estágio final de insuficiência renal crônica sob tratamento dialítico no Instituto de Nefrologia de Mogi das Cruzes, São Paulo, Brasil. Foram revistos os prontuários de 189 pacientes, com o objetivo de investigar a ocorrência de crises convulsivas durante o tratamento dialítico. Dos sete pacientes selecionados com história de crises, cinco concordaram em participar de nosso estudo. Três pacientes apresentaram crises generalizadas tônico-clônicas, um apresentou crise parcial com generalização subseqüente e um apresentou crise inclassificada. Três pacientes apresentaram crises apenas durante o processo dialítico (crise única) sendo que um deles apresentou status epilepticus convulsivo. Os outros dois pacientes já haviam apresentado crises antes do início do tratamento dialítico. Nós concluímos que as crises convulsivas que ocorrem em pacientes com falência renal podem ser consideradas como eventos ocasionais e que usualmente não se tornam crônicas.

Palavras-chave: crises epilépticas, epilepsia, diálise, falência renal.


 

 

Epilepsy is characterized by chronic recurrent paroxysmal changes in neurological functions caused by abnormalities in the electrical activity of the brain1. As epilepsy is considered to involve hyperexcitable neurons, a basic assumption in epilepsy research links the pathogenesis of epilepsy and the generation of synchronized neuronal activity with an imbalance between inhibitory [g-aminobutyric acid (GABA)-mediated] and excitatory (glutamate-mediated) neurotransmission in favor at the latter2. Approximately 2 million persons in the United States have epilepsy3,4 and each year, 100,000 new cases of epilepsy are diagnosed in the United States3,5. The most commonly reported etiological factors are stroke, tumors, alcohol, head injuries, congenital factors and neuroinfections6. In Brazil, neurocysticercosis is the most frequently identified cause of epilepsy7. Bergen and colleagues8 reported an estimated incidence of seizure of approximately 10% in patients with chronic renal failure. Moreover, Plum and Posner9 also noted that convulsions occurred in one third of patients with end-stage renal disease (ESRD) and was frequently a preterminal event. The seizures in these series usually were generalized tonic-clonic type, however, the mechanism of reduced seizure threshold in renal failure is still unknown.

Hemodialysis-associated seizure (HAS) is a common complication of hemodialysis10. HAS occurs in 7% to 50% of children with ESRD, and their seizures are usually reported as generalized tonic-clonic seizures11. On the other hand, non-convulsive seizures appear to be rare12,13. Risk factors for HAS include young age, prior history of seizures, malignant hypertension, microvascular diseases, uremic encephalopathy and cardiomyopathy. Moreover, induced brain water disequilibrium, hypocalcaemia, uremic toxins, the use of acetate in the dialysate, intracranial hemorrhage due to systemic heparinization, treatment with recombinant erytropoietin, hemodinamic and metabolic defects, and drugs such as penicillin and theophilline are also considered responsible for HAS11,14,15. The efficacy of anticonvulsant drugs in treating or preventing HAS is not well defined10,16. Diazepam is a non-dialyzable anticonvulsant drug17 and the administration of oral diazepam (0.3-0.5 mg/kg per dose) 30 minutes before each hemodialysis session may help to prevent recurrence of HAS10. On the other hand, readily dialyzable antiepileptic drugs such as phenobarbital may increase the risk of HAS16,18. Despite these observations, several lines of evidence support the idea that anaemia is one of the major limitations to rehabilitation in patients with ESRD. The efficacy of recombinant human erithropoietin in the treatment of renal anaemia is well established. However, this therapeutic approach has been associated with serious untoward effects: increased risk of hypertension, not infrequently accompanied by hypertensive encephalopathy and seizures19,20.

Based on these facts, the aim of our study was to investigate the occurrence of seizures in patients with ESRD under regular hemodialysis program.

 

METHOD

A retrospective medical history of 189 patients was reviewed to investigate the occurrence of convulsive seizures in dialysis patients at the Nephrology Institute of Mogi das Cruzes. From 189 patients under dialytic treatment, 7 had suffered some type of convulsive seizure and were invited to participate in the study, but only 5 patients had agreed to participate. They were 4 males and 1 female, with a mean age of 42 years (range 20 to 72 years old). The five patients have severe systemic arterial hypertension and were using antihypertensive drugs. In our clinic, all patients have monthly evaluation of total calcium and were receiving aluminum hydroxide. The solution for the dialytic treatment contains 0.89 gr. of NaCl/5 L, with a calcium concentration of 3.5 mEq/L.

All patients were evaluated for initial disease, duration, type and frequency of HAS and then submitted to clinical and neurological examination. The mean time of dialysis treatment and the electroencephalography (EEG) was analysed in all patients. The seizures were classified according the Commission on Classification and Terminology of International League Against Epilepsy21. The possible seizure triggering factors, such as the use or withdrawal of medications, sleep deprivation, arterial hypertension, infections, and electrolytic misbalance, especially hypocalcaemia, were also investigated.

 

RESULTS

In our study we analyzed the data of 5 out of 189 patients recruited under dialytic treatment at the Nephrology Institute of Mogi das Cruzes. All 5 patients had severe systemic arterial hypertension and were using antihypertensive drugs. These patients were also using antiepileptic drug (phenitoin 200 mg/daily) and CaCO3 (1500 mg/daily). The mean age of beginning of dialysis was 25 years. The mean duration of dialytic treatment was 5.8 years (range 2 to 12 years). The causes of renal failure were diabetic nephropathy (4 patients) and chronic glomerolonephritis (1 patient) (Table 1). All patients had normal aluminum plasma levels and were not affected by other clinical pictures that could be led to possible aluminum intoxication. The signs of Chvostek and Trousseau were absent in all patients and the neurological examination was normal in 4 patients, but one presented pyramidal syndrome (left hemiparesia with pyramidal signs), with abnormal CT scan (hipodensity on right temporal lobe).

 

 

The seizure history of the five patients is listed on Table 2. Briefly, three patients presented generalized tonic-clonic seizures, one presented partial seizure. with secondary generalization, and one presented unclassified seizure. All patients had seizures at home, two patients had seizures during dialysis procedure and one of them had presented convulsive status epilepticus. Two patients had already presented seizures prior the beginning of dialysis treatment; one of them without detectable structural central nervous system lesion, and the other showed hipodensity on right temporal lobe (vascular cerebral disease). All patients presented normal interictal EEG. At time of seizure, none of them presented infection, electrolytic misbalance (hypocalcemia), sleep deprivation or were using theophillin. All patients had anemia and were using erithropoetin.

 

 

DISCUSSION

Our study evaluated the occurrence of seizures in patients with ESRD under hemodialysis program. It has long been believed that seizures are relatively common events among patients with systemic diseases. HAS are commonly caused by metabolic encephalopathy, hypertensive crisis, infection, and dialysis disequilibrium13. We observed the occurrence of HAS in only 2% of our patients. In this way, our data are not in agreement with previous studies, which related an estimated incidence of seizure of approximately 10% in patients with chronic renal failure8.

The mechanism of reduced seizure threshold in renal failure is unknown. One possibility is the presence of proconvulsive metabolites, including guanidinosuccinic acid, creatinine, and creatine in human subjects22. Moreover, the epileptogenic potency of these compounds was further supported by animal studies23.

In spite of reports that prior history of seizure did influence the risk of seizures among patients receiving hemodialysis11, we did not observe higher risk in our patients who had prior history of epilepsy. It is difficult to make comparisons between our with other studies since different factors may influence the analysis, such as the age of the subjects, type of seizures and risk factors for HAS as previously mentioned.

It has long been believed that in the absence of prior clinically detected stroke, hypertension, particularly severe and uncontrolled; increase the risk of unprovoked seizures in older individuals24. Conversely, some studies did not find an association between hypertension and seizures in the absence of clinically detected stroke25,26. In addition, hypertension per se can induce alterations in the human brain morphology27, increasing the risk for clinically apparent brain dysfunction (e.g. epilepsy). In this way, despite a high prevalence of hypertensive diseases in patients with ESRD and the stroke been one of the commonly reported etiological factors, just one of our patients that presented seizures had preceding cerebrovascular stroke.

It has also been observed that anaemia is one of the major limitations to rehabilitation in patients with ESRD and the efficacy of recombinant human erithropoietin in the treatment of this condition is well established. All our patients presented anaemia and were using erithropoetin. This therapeutic approach has been associated with seizures and could justify the seizures in our patients that were using erithropoetin19,20.

At the present moment, the efficacy of antiepileptic drugs in treating or preventing HAS is not well defined. However, the administration of oral diazepam, a non-dialyzable drug, (0.3 - 0.5 mg/kg per dose) 30 minutes before each hemodialysis session has been shown to prevent the recurrence of HAS16. In our study, all patients were using phenitoin (200 mg/daily) which is in agreement with Rust and Chun16, who demonstrated that the use of phenobarbital, a dialyzable drug, did not prevent the HAS.

We conclude that seizures in renal failure can be considered as an occasional events that do not usually become chronic and information on the management of seizures in renal failure should be disseminated among professionals treating systemic diseases.

Acknowledgments – The authors would like to thank Dr. Paulo Gomes (University of Mogi das Cruzes) for his suggestions.

 

REFERENCES

1. Dichter MA. Emerging insights into mechanisms of epilepsy: implications for new antiepileptic drug development. Epilepsia 1994;35(Suppl 4):S51-S57.        [ Links ]

2. Dalby NO, Mody I. The process of epileptogenesis: a pathophysiological approach. Curr Opin Neurol 2001;14:187-192.        [ Links ]

3. Annegers JF. Epidemiology of epilepsy. In Wyllie E, (ed). The treatment of epilepsy: principles and practice, 2nd ed. Baltimore: Williams & Wilkins, 1997:165-172.         [ Links ]

4. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York: Demos, 1990.         [ Links ]

5. Begley CE, Annegers JF, Lairson LB, Reynolds TF. Epilepsy incidence, prognosis, and use of medical care in Houston, Texas, and Rochester, Minnesota. Epilepsia 1998;39(Suppl 6):S222.         [ Links ]

6. Halatchev VN. Epidemiology of epilepsy: recent achievements and future. Folia Med (Plovdiv) 2000;42:17-22.        [ Links ]

7. Basch EM, Cruz ME, Tapia D, Cruz A. Prevalence of epilepsy in a migrant population near Quito, Ecuador. Neuroepidemiology 1997;16:94-98.        [ Links ]

8. Bergen DC, Ristanovic R, Gorelick PB, Kathipalia S. Seizures and renal failures. Int J Artif Organs 1994;17:247-251.        [ Links ]

9. Plum F, Posner JB. Metabolic brain diseases causing coma. In Plum F, Posner JB (eds). The diagnosis of stupor and coma. Philadelphia: Davis, 1972.        [ Links ]

10. Sönmez F, Mir S, Tütüncüoglu S. Potential prophylatic use of benzodiazepines for hemodialysis-associated seizures. Pediatr Nephrol 2000; 14:367-369.        [ Links ]

11. Glenn CM, Astley SJ, Watkins SL. Dialysis associated seizures in children and adolescents. Int J Pediatr Nephrol 1992;6:182-186.        [ Links ]

12. Tanimu DZ, Obeid T, Awada A, Huaib S, Igbal A. Absence status; an overlooked cause of acute confusion in hemodialysis patients. J Nephrol 1998;11:146-147.        [ Links ]

13. Chow KM, Wang AY, Hui AC, Wong TY, Szeto CC, Li PK. Nonconvulsive status epilepticus in peritoneal dialysis patients. Am J Kidney Dis 2001;38:400-405.        [ Links ]

14. Swash M, Rowan AJ. Electroencephalographic criteria of hypocalcemia and hypercalcemia. Arch Neurol 1972;26:218-228.        [ Links ]

15. Schwartz RD. Hemodialysis associated seizures. In Nissensen AR, Fine RN (EDS) Dialysis therapy. Philadelphia Hanley Balfus, 1993:88-90.        [ Links ]

16. Rust RS, Chun WMR. Interrelationships between renal and neurologic diseases and therapies. In Swaiman KF, (ed). Pediatric neurology: Baltimore: Mosby, 1994:815-816.        [ Links ]

17. Sinaiko AR, O’ Dea RF. Use of drugs in renal insufficiency. In Edelmann CM, (ed). Pediatric kidney disease. Boston Little Brown, 1993:991-993.        [ Links ]

18. Burwen DR, Olsen SM, Bland LA, Archino MJ, Reid MH, Jarvis, WR. Epidemic aluminium intoxication in hemodialysis patients traced to use of an aluminium pump. Kidney Int 1995;48:469-474.        [ Links ]

19. Massetani R, Galli R, Calabrese R, Sartucci F, Rindi P, Severino B, Murri L. Status epilepticus in chronically dialyzed patients treated with erythropoietin. Riv Neurol 1991;61:215-218.        [ Links ]

20. Beccari M. Seizures in dialysis patients treated with recombinant erythropoietin: review of the literature and guidelines for prevention. Int J Artif Organs 1994;17:5-13.        [ Links ]

21. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.        [ Links ]

22. De Deyn PP, Mac Donald RR. Guanidino compounds that are increased and cerebrospinal fluid in brain of uraemic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol 1990; 28:627-633.        [ Links ]

23. D’Hooge R, Pei YQ, Marescau B, De Deyn PP. Convulsive action and toxicity of uremic guanidino compounds: behavioral assessment and relation to brain concentration in adult mice. J Neurol Sci 1992;12:96-105.        [ Links ]

24. Hesdorffer DC, Hauser WA, Annegers JF, Rocca WA. Severe, uncontrolled hypertension and adult-onset seizures: a case-control study in Rochester, Minnesota. Epilepsia 1996;37:736-741.        [ Links ]

25. Ng SK, Hauser WA, Brust JC, Susser M. Hypertension and the risk of new-onset unprovoked seizures. Neurology 1993;43:425-428.        [ Links ]

26. Shapiro IM, Neufeld MY, Korczyn AD. Seizures of unknown origin after the age of 50: vascular risk factors. Acta Neurol Scand 1990;82:78-80.        [ Links ]

27. Salerno JA, Murphy D G, Horwitz B, De Carli C, Haxby JV, Rapoport SL, Shapiro MB. Brain atrophy in hypertension: a volumetric magnetic resonance imaging study. Hypertension 1992;20:340-348.        [ Links ]

 

 

Received 21 February 2005, received in final form 5 May 2005. Accepted 16 June 2005.
FAEP, PRONEX, CNPq, and FAPESP supported this work.

 

 

Dr. Fulvio Alexandre Scorza - Rua Botucatu 862 / Disciplina de Neurologia Experimental UNIFESP - 04023-900 São Paulo SP - Brasil. E-mail: scorza.nexp@epm.br